Breaking WORLD PHARMA NEWS

Penn engineers turn toxic fungus into anti-cancer compound

Penn-led researchers have turned a deadly fungus into a potent cancer-fighting compound. After isolating a new class of molecules from Aspergillus flavus, a toxic crop fungus linked to deaths in the excavations of ancient tombs, the researchers modified the chemicals and tested them against leukemia cells. The result? A promising cancer-killing compound that rivals FDA-approved drugs and opens up new frontiers in the discovery of more fungal medicines.

Read more …

New drug for diabetes and obesity shows promising results

Lower blood sugar and increased fat burning - without negatively affecting appetite or muscle mass. These are some of the most promising effects of a new potential drug treatment for people with type 2 diabetes and obesity, according to a new study published in the journal Cell by researchers from Karolinska Institutet and Stockholm University.

Read more …

Article presents innovative drug for controlling weight and blood sugar

An article published in the journal Nature Metabolism presents an experimental drug that stimulates adipose tissue cells to produce heat through a process known as thermogenesis, thereby promoting weight loss. In animal tests, the compound prevented fat accumulation in response to a high-fat diet, treated existing obesity, and reversed associated metabolic disorders, including insulin resistance.

Read more …

Weekly semaglutide improves blood sugar and weight in adults with Type 1 diabetes

A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar and leads to substantial weight loss in adults with Type 1 diabetes who use automated insulin delivery systems.

The results were published in the journal NEJM Evidence.

Read more …

Targeting fusion protein's role in childhood leukemia produces striking results

Scientists at St. Jude Children's Research Hospital and Dana-Farber Cancer Institute today report the identification of a novel combination therapy approach to treat pediatric acute myeloid leukemia (AML). Standard treatment is often ineffective against AML, a cancer that commonly relapses with poor prognosis, particularly when the disease is fueled by fusion proteins involving NUP98.

Read more …

AI could accelerate protein engineering - key for developing new medicines

In a study published in the journal Nature Machine Intelligence, Sheffield computer scientists in collaboration with AstraZeneca and the University of Southampton have developed a new machine learning framework that has shown the potential to be more accurate at inverse protein folding than existing state-of-the-art methods.

Read more …

AstraZeneca enters strategic collaboration with CSPC Pharmaceuticals focused on AI-enabled research

AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group Limited. Working together on high priority targets, the collaboration aims to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications.

Read more …

Researchers identify a protein that may help improve the treatment of obesity and cardiovascular disease

Obesity, diabetes and cardiovascular diseases are increasingly present in the population. Brown adipose tissue has a protective function against these prevalent diseases, as it burns calories and can produce body heat from fat. But as the body ages, the activity of brown adipose tissue decreases. This inactivation of brown adipose tissue - also typical of obese people - remains poorly studied in the scientific literature.

Read more …

New strategy for the treatment of severe childhood cancer

Researchers at Karolinska Institutet and Lund University in Sweden have identified a new treatment strategy for neuroblastoma, an aggressive form of childhood cancer. By combining two antioxidant enzyme inhibitors, they have converted cancer cells in mice into healthy nerve cells. The study is published in the journal Proceedings of the National Academy of Sciences (PNAS).

Read more …

Groundbreaking TACIT algorithm offers new promise in diagnosing, treating cancer

Researchers at VCU Massey Comprehensive Cancer Center have developed a novel algorithm that could provide a revolutionary tool for determining the best options for patients - both in the treatment of cancer and in the prescription of medicines. As recently published in Nature Communications, Jinze Liu, Ph.D., and Kevin Byrd, D.D.S., Ph.D., created Threshold-based Assignment of Cell Types from Multiplexed Imaging Data (TACIT), which assigns cell identities based on cell-marker expression profiles.

Read more …